MCID: KLT001
MIFTS: 50

Klatskin's Tumor

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Klatskin's Tumor

MalaCards integrated aliases for Klatskin's Tumor:

Name: Klatskin's Tumor 12 52 15 17
Klatskin Tumor 12 52 58 6 43 71
Hilar Cholangiocarcinoma 12 58 17
Perihilar Cholangiocarcinoma 52 71
Perihilar Extrahepatic Bile Duct Carcinoma 12
Hilar Cholangiocellular Carcinoma 12
Hilar Cca 58

Characteristics:

Orphanet epidemiological data:

58
klatskin tumor
Inheritance: Not applicable; Age of onset: Adult; Age of death: adult;

Classifications:

Orphanet: 58  
Rare hepatic diseases


External Ids:

Disease Ontology 12 DOID:4927
MeSH 43 D018285
NCIt 49 C36077
SNOMED-CT 67 6492006
MESH via Orphanet 44 D018285
ICD10 via Orphanet 33 C24.0
UMLS via Orphanet 72 C0206702
Orphanet 58 ORPHA99978
UMLS 71 C0206702 C4045991

Summaries for Klatskin's Tumor

NIH Rare Diseases : 52 Klatskin tumors are are a type of cholangiocarcinoma that begins in an area called the hilum, where the left and right bile ducts join and leave the liver. It is the most common type of cholangiocarcinoma, accounting for more than half of all cases. Symptoms usually don't present until advanced stages of disease, when jaundice is the most common feature. Other symptoms include abdominal pain, unintentional weight loss, and a general feeling of being unwell (malaise ). The cause of Klatskin tumors is unknown. Studies suggest that a combination of genetic, environmental, and lifestyle factors (multifactorial ) likely influence whether a person will develop cholangiocarcinoma. Because Klatskin tumors are often discovered after they have spread, they can be challenging to treat. Surgical removal of the tumor and relief of bile duct blockage are the main goals of treatment.

MalaCards based summary : Klatskin's Tumor, also known as klatskin tumor, is related to sclerosing cholangitis and liver lymphoma, and has symptoms including abdominal pain, icterus and malaise. An important gene associated with Klatskin's Tumor is MIR373 (MicroRNA 373), and among its related pathways/superpathways are Matrix Metalloproteinases and Colorectal Cancer Metastasis. The drugs Bilirubin and Bismuth have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and b cells, and related phenotypes are jaundice and extrahepatic cholestasis

Disease Ontology : 12 An intrahepatic cholangiocarcinoma arising near or at the confluence of the right and left hepatic ducts.

Wikipedia : 74 A Klatskin tumor (or hilar cholangiocarcinoma) is a cholangiocarcinoma (cancer of the biliary tree)... more...

Related Diseases for Klatskin's Tumor

Diseases related to Klatskin's Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 338)
# Related Disease Score Top Affiliating Genes
1 sclerosing cholangitis 30.9 GPT CEACAM5 ALB
2 liver lymphoma 30.4 CEACAM5 AFP
3 choledocholithiasis 30.2 GPT CEACAM5 ALB
4 biliary tract benign neoplasm 30.2 KRT7 CEACAM5
5 biliary papillomatosis 30.1 KRT7 CEACAM5
6 acute cholangitis 30.1 GPT CEACAM5 ALB
7 hepatic tuberculosis 30.0 GPT ALB
8 cholecystolithiasis 30.0 GPT CEACAM5
9 cholangitis 30.0 GPT CEACAM5 ALB
10 krukenberg carcinoma 29.9 KRT7 CEACAM5
11 appendix adenocarcinoma 29.9 KRT7 CEACAM5
12 pancreatic adenocarcinoma 29.9 MMP9 MMP2 MMP14 APC ALB
13 paralytic ileus 29.8 GPT ALB
14 adenocarcinoma 29.8 MMP9 MMP2 MALAT1 KRT7 CEACAM5 APC
15 cholangitis, primary sclerosing 29.5 PRRT2 PCCA KRT7 GPT ALB
16 intrahepatic cholangiocarcinoma 29.5 KRT7 APC ALB AFP
17 tubular adenocarcinoma 29.5 KRT7 CEACAM5 AFP
18 cystadenoma 29.5 KRT7 CEACAM5 AFP
19 bile duct cystadenocarcinoma 29.3 KRT7 CEACAM5 AFP
20 liver sarcoma 29.3 KRT7 CEACAM5 AFP
21 liver cirrhosis 29.3 MALAT1 GPT ALB AFP
22 viral hepatitis 29.0 GPT ALB AFP
23 cholangiocarcinoma 28.9 MMP9 MIR373 MALAT1 KRT7 CEACAM5 APC
24 gallbladder cancer 28.8 MMP9 MMP2 MALAT1 KRT7 CEACAM5 APC
25 lung cancer susceptibility 3 28.7 MMP9 MMP2 MMP14 MALAT1 KRT7 CEACAM5
26 gastric adenocarcinoma 28.5 MMP9 MMP2 KRT7 CEACAM5 APC AFP
27 bile duct cancer 28.4 MMP2 KRT7 GPT CEACAM5 ALB AFP
28 bile duct adenocarcinoma 27.9 PRRT2 PCCA KRT7 CEACAM5 ALB AFP
29 biliary tract disease 27.7 PRRT2 KRT7 GPT CEACAM5 ALB AFP
30 bile duct disease 27.4 PRRT2 PCCA KRT7 GPT CEACAM5 ALB
31 hepatocellular carcinoma 27.1 MMP9 MMP2 MMP14 MALAT1 KRT7 GPT
32 extracranial arteriovenous malformation 10.6 MMP9 MMP2
33 focal myositis 10.6 MMP9 MMP2
34 lentigo maligna melanoma 10.6 MMP9 MMP2
35 acute transverse myelitis 10.6 MMP9 MMP2
36 transverse myelitis 10.6 MMP9 MMP2
37 nasal cavity squamous cell carcinoma 10.5 MMP9 MMP2
38 multicentric osteolysis-nodulosis-arthropathy spectrum 10.5 MMP2 MMP14
39 spastic entropion 10.5 MMP9 MMP2
40 winchester syndrome 10.5 MMP2 MMP14
41 odontogenic myxoma 10.5 MMP9 MMP2
42 cholestasis 10.4
43 bilirubin metabolic disorder 10.4
44 rare tumor 10.4
45 colon adenoma 10.4 MMP2 MACC1 APC
46 senile ectropion 10.4 MMP9 MMP2
47 light chain deposition disease 10.4 MMP9 MMP2 MMP14
48 aortic aneurysm, familial abdominal, 1 10.4 MMP9 MMP2 MMP14
49 biliary tract cancer 10.3
50 hyperostosis 10.3 MMP9 MMP2 MMP14

Graphical network of the top 20 diseases related to Klatskin's Tumor:



Diseases related to Klatskin's Tumor

Symptoms & Phenotypes for Klatskin's Tumor

Human phenotypes related to Klatskin's Tumor:

58 31 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 jaundice 58 31 hallmark (90%) Very frequent (99-80%) HP:0000952
2 extrahepatic cholestasis 58 31 hallmark (90%) Very frequent (99-80%) HP:0012334
3 cholangiocarcinoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0030153
4 hepatomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0002240
5 lymphadenopathy 58 31 frequent (33%) Frequent (79-30%) HP:0002716
6 fatigue 58 31 occasional (7.5%) Occasional (29-5%) HP:0012378
7 fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0001945
8 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
9 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
10 venous thrombosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0004936

UMLS symptoms related to Klatskin's Tumor:


abdominal pain, icterus, malaise

GenomeRNAi Phenotypes related to Klatskin's Tumor according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.5 AFP
2 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.5 AFP
3 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.5 APC
4 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.5 KRT7
5 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.5 APC
6 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.5 AFP APC KRT7
7 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.5 APC
8 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.5 AFP APC
9 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.5 APC
10 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.5 AFP
11 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.5 APC KRT7

MGI Mouse Phenotypes related to Klatskin's Tumor:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.1 AFP ALB APC MBD2 MMP2 MMP9

Drugs & Therapeutics for Klatskin's Tumor

Drugs for Klatskin's Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bilirubin Phase 4 635-65-4, 69853-43-6 5280352 21252250
2
Bismuth Phase 4 7440-69-9 16682734 105143
3
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
4
Trioxsalen Approved Phase 3 3902-71-4 5585
5
s 1 (combination) Phase 3
6 Ether Phase 3
7 Hematoporphyrins Phase 3
8 Hematoporphyrin Derivative Phase 3
9 Dermatologic Agents Phase 3
10 Dihematoporphyrin Ether Phase 3
11 Photosensitizing Agents Phase 3
12
Floxuridine Approved Phase 1, Phase 2 50-91-9 5790
13
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
14
Trametinib Approved Phase 2 871700-17-3 11707110
15
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
16
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
17
Temoporfin Approved, Investigational Phase 2 122341-38-2
18
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
19
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
20
leucovorin Approved Phase 2 58-05-9 6006 143
21
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
22
Gemcitabine Approved Phase 2 95058-81-4 60750
23
Ceritinib Approved Phase 2 1032900-25-6
24
Fluorouracil Approved Phase 2 51-21-8 3385
25
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
26
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
27
Pancrelipase Approved, Investigational Phase 2 53608-75-6
28
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
29
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
30
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
31 Trace Elements Phase 2
32 Vitamins Phase 2
33 Micronutrients Phase 2
34 Vitamin B Complex Phase 2
35 Vitamin B9 Phase 2
36 Nutrients Phase 2
37 Folate Phase 2
38 Calcium, Dietary Phase 2
39 Protective Agents Phase 2
40 Antidotes Phase 2
41 Hormones Phase 2
42 Angiogenesis Inhibitors Phase 1, Phase 2
43 Antineoplastic Agents, Immunological Phase 1, Phase 2
44 Anti-Inflammatory Agents Phase 2
45 topoisomerase I inhibitors Phase 2
46 Topoisomerase Inhibitors Phase 2
47 Antibodies, Monoclonal Phase 1, Phase 2
48 Immunoglobulins Phase 1, Phase 2
49 Antibodies Phase 1, Phase 2
50 Immunologic Factors Phase 2

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 Effect of Preoperative Biliary Drainage on Postoperative Complications in Resectable Patients With Hilar Cholangiocarcinoma(Klatskin Tumor) Unknown status NCT00797121 Phase 4
2 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent: A Randomized Control Trial Unknown status NCT00746538 Phase 4
3 Uncovered Self-expandable Metal Stent Versus DoubleLayer Plastic Stent for Malignant Hilar Stricture: a Prospective Randomized Multicenter Trial Unknown status NCT01125865 Phase 4
4 Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Unresectable Complex Hilar Cholangiocarcinoma; a Randomized Controlled Trial Completed NCT00721175 Phase 4
5 Photodynamic Therapy With S-1 in the Patients With Unresectable Type III or IV Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control Completed NCT00869635 Phase 3 S-1 Chemotherapy
6 Sequential Preoperative Ipsilateral Hepatic Vein Embolization After Portal Vein Embolization to Induce Further Liver Regeneration in Patients With Hepatobiliary Malignancy Completed NCT00698880 Phase 2, Phase 3
7 Percutaneous Bilateral Versus Unilateral Metal Stent Placement for Hilar Cholangiocarcinoma : A Prospective Open-label Randomized Controlled Trial Recruiting NCT02108145 Phase 2, Phase 3
8 Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
9 Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma Terminated NCT02082522 Phase 3 Photodynamic therapy-Photofrin;Chemotherapy regimen
10 Phase 1 Study of Liver Transplantation Combined With Neoadjuvant Radiochemotherapy for Unresectable Hilar Cholangiocarcinoma Unknown status NCT02178280 Phase 1, Phase 2
11 Photodynamic Therapy Using a Novel Photosensitizer in Locally Advanced Hilar Cholangiocarcinoma Unknown status NCT02725073 Phase 2
12 Downstaging of Unresectable Intrahepatic or Hilar Cholangiocellular Carcinoma by Selective Intra-arterial Floxuridine and Systemic Cisplatin and Gemcitabine. A Dose Finding Single Center Phase IIa Study Completed NCT01692704 Phase 1, Phase 2 Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin
13 Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
14 Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer Completed NCT02042443 Phase 2 Capecitabine;Fluorouracil;Leucovorin Calcium;Trametinib
15 Cholangiocarcinoma Detection Using an Intraoperative Fluorescence Image Guided Approach With Bevacizumab-IRDye 800CW Recruiting NCT03620292 Phase 1, Phase 2 Bevacizumab-IRDye800CW
16 A Phase IIA Study of ABC294640 in the Treatment of Patients With Advanced, Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma Recruiting NCT03377179 Phase 2 ABC294640
17 Safety and Tumoricidal Effect of Low Dose Temoporfin Photodynamic Therapy in Patients With Inoperable Bile Duct Cancers (Foscan® Study) Recruiting NCT03003065 Phase 2 Temoporfin
18 REGORAFENIB AFTER FAILURE OF GEMCITABINE AND PLATINUM-BASED CHEMOTHERAPY FOR LOCALLY ADVANCED (NON RESECTABLE) AND METASTATIC INTRA-HEPATIC OR HILAR CHOLANGIOCARCINOMA: A Randomized Double-blinded Phase II Trial. Active, not recruiting NCT02162914 Phase 2 Regorafenib/active;Regorafenib/placebo
19 Phase II Trial of Modified FOLFIRINOX in Patients With Metastatic Biliary Tract Cancer After Failure of Gemcitabine/Cisplatin Chemotherapy Not yet recruiting NCT03778593 Phase 2 5-Fluorouracil;Leucovorin;Irinotecan;Oxaliplatin
20 A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Not yet recruiting NCT04068194 Phase 1, Phase 2 Avelumab;Nedisertib
21 Multi-center, Randomized, Controlled, Open-label Study of Deuteporfin Photodynamic Therapy Plus Stenting Versus Stenting Alone as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma Terminated NCT02955771 Phase 2
22 A Phase II Trial of LDK378 as the First or Second-line Therapy in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma Terminated NCT02374489 Phase 2 LDK378
23 Phase II Study of Stereotactic Body Radiotherapy (SBRT) and Chemotherapy for Unresectable Cholangiocarcinoma Followed by Liver Transplantation Terminated NCT01151761 Phase 2 Gemcitabine;Cisplatin;Carboplatin;Capecitabine;5FU
24 A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma Terminated NCT02254681 Phase 2 Gemcitabine;Cisplatin
25 Definitive Chemoradiation With Gemcitabine and Continuous 5- FU (Fluorouracil)Followed by High Dose Rate Brachytherapy or Stereotactic Body Radiation Therapy Boost in Locally Advanced Intra or Extrahepatic Cholangiocarcinoma Terminated NCT00983541 Phase 2 Fluorouracil (5-FU);Gemcitabine
26 A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Amphinex®-Induced Photochemical Internalisation (PCI) of Gemcitabine in Patients With Advanced Inoperable Cholangiocarcinomas Completed NCT01900158 Phase 1 Amphinex, Gemcitabine and Cisplatin
27 A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients With Unresectable or Metastatic Pancreatic and Biliary Tract Cancers Completed NCT01825603 Phase 1 ADH-1;Cisplatin;Gemcitabine Hydrochloride
28 Phase I Dose Escalation Trial of External Beam Radiation and Cyberknife Radiosurgery Boost With Concurrent Capecitabine for Hilar Cholangiocarcinoma (Klatskin Tumor) Terminated NCT00630890 Phase 1
29 A Phase Ib, Open-Label, Dose- Escalation Trial of ACY-1215 in Combination With Gemcitabine and Cisplatin in Patients With Unresectable or Metastatic Cholangiocarcinoma Withdrawn NCT02856568 Phase 1 Cisplatin;Gemcitabine Hydrochloride;Ricolinostat
30 Trapianto di Fegato Per Colangiocarcinoma (CCA) Ilare in Associazione a Radio e Chemioterapia Neoadiuvante Unknown status NCT01549795 Capecitabine
31 Superior Bilioenteric Anastomosis by Magnetic Compressive Technique: A Multicenter, Prospective, Randomized Controlled Trial Unknown status NCT02801500
32 Application of Endoscopic Scissors Cutting Endoscopic Nasobiliary Drainage Tube in the Treatment of Malignant Hilar Biliary Strictures: a Multicenter, Prospective, Randomized Controlled Study Unknown status NCT03353181
33 The Predictor of Infectious Complication After Hepatopancreatobiliary Surgery and Monitoring Indicator of Anti-infectious Therapy Unknown status NCT02878668
34 Optimization of Health Expenditure in Major Surgery: Impact of a Mixed, Clinical and Ethnographic Approach in the Model of Liver Surgery Unknown status NCT01715402
35 Exploratory Phase IV Randomized Single Blind Study Evaluating the Efficacy and Tolerability of Hemopatch in Improving Time of Hemostasis and Preventing Post-operative Complications After Hepatic Resection Unknown status NCT03323359
36 Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection? Completed NCT00733200
37 Long-term Morbidity After Surgery for Perihilar Cholangiocarcinoma; a Cohort Study Completed NCT03999593
38 Single Versus Multiple Deployment of Metallic Stents for Inoperable Malignant Hilar Biliary Obstruction: A Multicenter Prospective Randomized Study Completed NCT02166970
39 The Role of Gadoxetate Enhanced Spectral Dual-Energy CT in Evaluating Hilar Cholangiocarcinoma Completed NCT01673802 Early Phase 1 CT scan
40 Split-in-situ Resection With Radio-frequency Ablation Instead of Liver Partition on the First Stage (RALPPS) in Patients With Hilar and Intrahepatic Cholangiocarcinoma Completed NCT03320980
41 Photodynamic Therapy With Polyhematoporphyrin for Malignant Biliary Obstruction - a Retrospective Analysis. Completed NCT02504957
42 Best Biliary Drainage Option in Type II、III、IV Klatskin Tumor:ERCP or PTBD Completed NCT03104582
43 Observational Study for Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma Completed NCT01506115 Photofrin
44 Impact of Three-dimensional Visualization on Operation Strategy and Complications for Hilar Cholangiocarcinoma Recruiting NCT03132649
45 A Pilot Study to Determine the Feasibility of Stereotactic Body Radiation Therapy Following Chemotherapy for Unresectable Perihilar Cholangiocarcinoma. "The STRONG Trial" Recruiting NCT03307538
46 Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma: A Prospective Double-blind Multicenter Randomized Controlled Study Recruiting NCT03104569
47 Randomized Prospective Multicentric Study: Radio-chemotherapy and Liver Transplantation Versus Liver Resection to Treat Respectable Hilar Cholangiocarcinoma Recruiting NCT02232932
48 Effectiveness of Prophylactic Antibiotics to Prevent Post Endoscopic Retrograde Cholangio Pancreatography Bacteremia in Biliary Obstruction Patient Recruiting NCT02958059
49 Randomized Clinical Trial Comparing Three Dimension Laparoscopic and Open Surgery for Perihiliar Cholangiocarcinoma Recruiting NCT03383796
50 Expanded Access to ABC-108, A Phase IIA Study of ABC294640 in the Treatment of Patients With Advanced,Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma Available NCT03414489 ABC294640

Search NIH Clinical Center for Klatskin's Tumor

Cochrane evidence based reviews: klatskin tumor

Genetic Tests for Klatskin's Tumor

Anatomical Context for Klatskin's Tumor

MalaCards organs/tissues related to Klatskin's Tumor:

40
Liver, Colon, B Cells, Ovary, Appendix, Lung, Testis

Publications for Klatskin's Tumor

Articles related to Klatskin's Tumor:

(show top 50) (show all 278)
# Title Authors PMID Year
1
Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar cholangiocarcinoma. 46
21165562 2011
2
Klatskin-mimicking neuroendocrine tumor. 61
31696723 2019
3
Acute mental change as the presenting sign of posthepatectomy hepatic failure: A case report. 61
31770264 2019
4
Percutaneous Hepaticojejunostomy across an Isolated Bile Duct after Klatskin Tumor Resection. 61
31349977 2019
5
Clinical features of isolated proximal-type immunoglobulin G4-related sclerosing cholangitis. 61
30570170 2019
6
Radiotherapy or Chemoradiation in Unresectable Biliary Cancer: A Retrospective Study. 61
31177154 2019
7
Liver Transplant for Perihilar Cholangiocarcinoma (Klatskin Tumor): The Essential Role of Patient Selection. 61
29911960 2019
8
Klatskin Tumor: A Population-Based Study of Incidence and Survival. 61
31204730 2019
9
Heterotopic chondroid tissue of the main bile duct mimicking Klatskin tumor: case report and review of the literature. 61
30499056 2019
10
Hepatic hilar mass in an adolescent: a rare case of hepatobiliary tuberculosis. 61
30832669 2019
11
Ultrasound-guided percutaneous irreversible electroporation of hepatic and abdominal tumors not eligible for surgery or thermal ablation: a western report on safety and efficacy. 61
30843171 2019
12
Primary large cell neuroendocrine carcinoma of the common hepatic duct mimicking a Klatskin tumor. 61
29466852 2019
13
Klatskin tumors and "Klatskin-mimicking lesions": our 22-year experience. 61
30421957 2019
14
Concomitant adenosquamous carcinoma and cystadenocarcinoma of the extrahepatic bile duct: A case report. 61
30705898 2019
15
Preoperative Portal Vein Embolization Alone with Biliary Drainage Compared to a Combination of Simultaneous Portal Vein, Right Hepatic Vein Embolization and Biliary Drainage in Klatskin Tumor. 61
30238334 2018
16
[Cavernoma complicated with biliopatia secondary to type 1 Gaucher disease: report of a Peruvian case]. 61
30540732 2018
17
IgG4-related sclerosing cholangitis mimicking hilar cholangiocarcinoma (Klatskin tumor): a case report of a challenging disease and review of the literature. 61
31579779 2018
18
Patient With Unresectable Cholangiocarcinoma Treated With Radiofrequency Hyperthermia in Combination With Chemotherapy: A Case Report. 61
28745084 2018
19
Gerald Klatskin (1910-1986): A pioneer in hepato-biliary disorders and biopsy techniques. 61
29998747 2018
20
Metastatic Pancreatic Adenocarcinoma Presenting as a Klatskin Tumor. 61
30568968 2018
21
[Cholangiocellular cancer: the state of the problem and ways to improve the results of surgical treatment]. 61
30560842 2018
22
Mirizzi Syndrome: Diagnosis and Management of a Challenging Biliary Disease. 61
30159303 2018
23
Klatskin Tumor. 61
28985102 2017
24
Best option for preoperative biliary drainage in Klatskin tumor: A systematic review and meta-analysis. 61
29069029 2017
25
Hepatoduodenal lymph node metastasis mimicking Klatskin tumor in a patient with sigmoid colon mucinous cancer. 61
28828110 2017
26
Single synchronous liver metastasis from Merkel cell carcinoma mimicking a klatskin tumor: A diagnostic challenge. 61
28473299 2017
27
Preoperative biliary drainage versus direct surgery for perihilar cholangiocarcinoma: A retrospective study at a single center. 61
28529266 2017
28
Primary Hepatic Lymphoma Mimicking Cholangiocarcinoma. 61
28804587 2017
29
Primary extrahepatic bile duct neuroendocrine tumor with obstructive jaundice masquerading as a Klatskin tumor. 61
28596824 2017
30
Evaluation of Tumor Markers and Their Impact on Prognosis in Gallbladder, Bile Duct and Cholangiocellular Carcinomas - A Pilot Study. 61
28373474 2017
31
Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: A nationwide retrospective study of 150 consecutive applications. 61
28405328 2017
32
Mortality after portal vein embolization: Two case reports. 61
28178122 2017
33
Extrahepatic biliary obstrution secondary to neuroendocrine tumor of the common hepatic duct. 61
27902955 2017
34
Best options for preoperative biliary drainage in patients with Klatskin tumors. 61
27287904 2017
35
Bilateral ovarian metastasis of a Klatskin tumor: A rare case. 61
28913125 2016
36
A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer. 61
27586966 2016
37
Associating Liver Partition and Portal Vein Ligation for Primary Hepatobiliary Malignancies and Non-Colorectal Liver Metastases. 61
26929296 2016
38
Isolated Liver Hilar Infiltration by IgG4 Inflammation Mimicking Cholangiocarcinoma. 61
27843427 2016
39
The Klatskin Tumor That Wasn't: An Unusual Presentation of Sarcoidosis. 61
27761479 2016
40
Y-configured metallic stent combined with (125)I seed strands cavity brachytherapy for a patient with type IV Klatskin tumor. 61
27648091 2016
41
Palliative Locoregional Treatment for Unresectable Nonmetastatic Klatskin Tumor: Percutaneous Transhepatic Biliary Drainage Combined With 3-dimensional Conformal Radiotherapy. 61
27035079 2016
42
[Operation treatment method of Bismuth-Corlette Ⅲ, Ⅳ hilar cholangiocarcinoma]. 61
27373472 2016
43
[Klatskin tumor: long-term survival following surgery]. 61
27090415 2016
44
Endobronchial Watanabe Spigot in the treatment of bronchobiliary fistula. 61
27374219 2016
45
Atypical presentation of a hepatic artery pseudoaneurysm: A case report and review of the literature. 61
27366305 2016
46
Stent placement above the sphincter of Oddi permits implementation of neoadjuvant chemotherapy in patients with initially unresectable Klatskin tumor. 61
27092322 2016
47
Percutaneous "Y" biliary stent placement in palliative treatment of type 4 malignant hilar stricture. 61
27034794 2016
48
Neuroendocrine Carcinoma of the Gallbladder Masquerading as a Klatskin Tumor in a 74-Year-Old Male. 61
26036328 2016
49
[Klatskin tumor - a case report]. 61
27000815 2016
50
[Percutaneous cholangiostomy for portal cholangiocarcinoma]. 61
27723691 2016

Variations for Klatskin's Tumor

ClinVar genetic disease variations for Klatskin's Tumor:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 APC NM_000038.6(APC):c.4658C>T (p.Ala1553Val)SNV Uncertain significance 559953 rs1554086050 5:112175949-112175949 5:112840252-112840252

Expression for Klatskin's Tumor

Search GEO for disease gene expression data for Klatskin's Tumor.

Pathways for Klatskin's Tumor

Pathways related to Klatskin's Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.54 MMP9 MMP2 MMP14
2 11.47 MMP9 MMP2 MMP14 APC
3 11.4 MMP9 MMP2 APC
4 11.25 MMP9 MMP2 MMP14
5 11.12 MMP9 MMP2 MMP14
6 11.01 MMP9 MMP2 MMP14 CEACAM5

GO Terms for Klatskin's Tumor

Biological processes related to Klatskin's Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to amyloid-beta GO:1904645 9.37 MMP9 MMP2
2 extracellular matrix disassembly GO:0022617 9.33 MMP9 MMP2 MMP14
3 tissue remodeling GO:0048771 9.32 MMP2 MMP14
4 transport GO:0006810 9.26 ALB AFP
5 collagen catabolic process GO:0030574 9.13 MMP9 MMP2 MMP14
6 endodermal cell differentiation GO:0035987 8.8 MMP9 MMP2 MMP14

Molecular functions related to Klatskin's Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metalloendopeptidase activity GO:0004222 8.8 MMP9 MMP2 MMP14

Sources for Klatskin's Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....